Videos

Panelists discuss how to manage PIK3CA inhibitor toxicities through frequent early monitoring, patient education about warning signs, use of continuous glucose monitors (CGMs) when needed, and willingness to interrupt treatment and reduce doses while maintaining patients on therapy long term.

Gedatolisib triplet and doublet regimens cut the risk of progression by up to 76% vs fulvestrant in HR-positive/HER2-negative advanced breast cancer.

Experts discuss the importance of early multidisciplinary collaboration in breast cancer care, particularly involving radiation oncology at diagnosis.

Experts discuss how a multidisciplinary clinic streamlines care and improves treatment planning for patients with newly diagnosed breast cancer.

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

Kelly E. McCann, MD, PhD, details the current standard of care and novel approaches for the treatment of ER-positive, HER2-negative advanced breast cancer.

The European Commission has approved inavolisib plus palbociclib/fulvestrant in PIK3CA-mutant ER-positive, HER2-negative advanced breast cancer.

Panelists discuss how the SERENA-6 trial’s approach of serial liquid biopsy monitoring for ESR1 mutations raises important questions about the optimal timing and clinical benefit of molecularly guided therapy switches, with both experts preferring to see overall survival data before changing practice patterns.

Panelists discuss how biomarker testing strategies have evolved from second-line to first-line metastatic disease, driven by the availability of targeted agents for PIK3CA and ESR1 mutations, with both tissue and liquid biopsy approaches being used to ensure timely results for treatment decision-making.

PF-07248144 is a first-in-class selective inhibitor of KAT6A and KAT6B that has displayed the ability to suppress ER expression in a preclinical study.

Hope S. Rugo, MD, discusses the safety profile of alpelisib for the treatment of PI3K-mutant HR-positive/HER2-negative advanced breast cancer.

Panelists discuss how nonclinical factors including drug costs, insurance coverage, work situations, patient intelligence for complex dosing schedules, and comprehensive pretreatment education about toxicities like hyperglycemia, rash, and diarrhea are crucial for successful implementation of the triplet regimen.

Panelists discuss how to identify ideal candidates for triplet therapy using a case example, emphasizing the importance of endocrine resistance, disease burden, performance status, and careful management of hyperglycemia risk through baseline hemoglobin A1C (HbA1C) assessment and proactive glucose monitoring strategies.

Jade E. Jones, MD, discusses the importance of identifying the most effective first-line treatment regimen for PD-L1–positive TNBC.

Adjuvant dalpiciclib plus endocrine therapy met the iDFS primary end point in the DAWNA-A trial in HR-positive, HER2-negative early breast cancer.

Antoinette Tan, MD, MHS, discusses the implications of the DESTINY-Breast06 trial of T-DXd vs chemotherapy in HER2-low or -ultralow breast cancer.

Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.

Treatment with HER3-DXd led to intracranial responses with a tolerable safety profile in patients with metastatic breast cancer and brain metastases.

Real-world analysis showed ctDNA positivity was associated with higher recurrence risk and reduced overall survival in early breast cancer.

Panelists discuss how to contextualize inavolisib within the broader landscape of PIK3CA inhibitors, noting its improved tolerability compared with alpelisib while emphasizing the need for individualized treatment selection based on disease burden and the emerging challenge of managing comutations like ESR1.

Panelists discuss how the INAVO120 trial’s secondary end point showing delayed time to chemotherapy from 12 to 36 months with the triplet combination provides compelling quality-of-life benefits for patients while acknowledging the challenges of determining optimal treatment sequencing after progression on this regimen.

Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

Fatima Cardoso, MD, MSc, FESMO, discusses the use of elinzanetant for vasomotor symptoms in women receiving endocrine therapy for HR+ breast cancer.

Katherine C. Ansley, MD, discusses the importance of the phase 3 INAVO120 trial in PIK3CA-mutated, hormone receptor–positive, HER2-negative breast cancer.

Panelists discuss how the INAVO120 trial's final overall survival analysis showing a 7-month median survival benefit (34 vs 27 months) with inavolisib plus palbociclib plus fulvestrant in PIK3CA-mutated endocrine resistant breast cancer represents promising but complex data, given the low crossover rates and potential need for first-line PIK3CA inhibitor use before patients progress to chemotherapy.

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Nagi S. El-Saghir, MD, FACP, FASCO, discusses the clinical implications of the phase 2 RIGHT Choice trial.

Kelly McCann, MD, PhD, discusses the need to reach consensus on the potential role of vepdegestrant for ER-positive, HER2-negative advanced breast cancer.